AI-generated analysis. Always verify with the original filing.
Elicio Therapeutics, Inc. entered into an At Market Issuance Sales Agreement on March 16, 2026, with B. Riley Securities, Inc., JonesTrading Institutional Services LLC, and Ladenburg Thalmann & Co. Inc. to issue and sell up to $100.0 million of common stock through an at-the-market offering program. The company simultaneously terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had a $40.0 million capacity and no termination penalties.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (t
Termination of a Material Definitive Agreement. As previously disclosed on June 3, 2024, the Company entered into a Capital on Demand™ Sales Agreement with Jone
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., dated Ma
Material Agreement